[ad_1]
Rubella is the contagious viral infection of the respiratory system. Rubella is also known as German measles. Rubella is not similar to measles, although they have similar characteristics, like red rushes, but they are caused by a different virus. The rubella virus causes joint pain, mild fever, sore throat and rash. About 25% to 50% of people infected with the rubella virus have no symptoms. The rubella virus spreads in the air or through close contact. It is usually transmitted when the person comes in direct contact with the respiratory secretion of an infected person, such as a mucus. Rubella can cause serious problems, including arthritis and bleeding problems. Very serious rubella infection during pregnancy, it can cause a variety of conbad malformations and miscarriages. Most serious problems occur because rubella is a harm to a baby. There is no specific treatment available for rubella. Vaccination against rubella is recommended for the prevention of rubella infection. Unvaccinated women have a 90% chance that the fetus will have conbad rubella syndrome. Symptomatic treatment is available to reduce the risk of complications and relieve symptoms. Paracetamol, ibuprofen, aspirin can be used to reduce high temperatures and treat acne and pain.
Sample Report Request @ https://www.persistencemarketresearch.com/samples/23029
High risk of complication of infected rubella. Pregnant women and the largest number of unvaccinated children and adults are the main factors contributing to the growth of the rubella treatment market. Manufacturers increasingly focused on the development of drugs for rare diseases, increasing health care awareness, government programs to maintain the health of pregnant women should be another factor driving the growth of the drug treatment market. rubella. Failure to vaccinate children against measles and rubella exposes them to serious complications, such as brain damage, deafness and blindness. The increasing failure of vaccination will stimulate the demand for drugs that are used for symptomatic treatment and, may indirectly contribute to the growth of the rubella treatment market. No specific treatment is available for rubella infection, which is a major factor hindering the growth of the rubella treatment market.
The global rubella drug market is segmented by drug type, route of administration, and route of distribution:
- Type of drug
- Non-steroidal anti-inflammatory drugs
- Analgesic
]
- Segmentation by way of administration
- Segmentation by End User
- Hospital Pharmacies
- Pharmacies
- Online Pharmacies
- Retail Pharmacies
Nonsteroidal anti-inflammatory drugs and badgesics are used to treat rubella or reduce the symptoms. These medications relieve pain, reduce itching and control the fever due to rubella infection. Rubella infection is dangerous during pregnancy If a woman contracts rubella until 13 weeks of pregnancy, there is a very high risk that the baby may be infected with measles. Baby can develop problems such as loss of sight or hearing.
At the regional level, the global market for rubella treatment is segmented into six key regions. North America, Latin America, Europe, Asia-Pacific Excluding China, China and the Middle East and Africa. North America is expected to be leading the global market due to the increase in drug manufacturing facilities and strong awareness of infectious diseases. Europe also has the second-fastest growing market for rubella treatment due to stringent laws and government guidelines regarding the health of children and mothers. In addition, the rubella treatment market in the Asia-Pacific region is expected to experience significant growth over the forecast period as a result of increasing government initiatives to reduce the complication of the disease among patients. children. More than 60% of the 21.5 million children who did not receive a vaccine dose in 2013 come from 6 counties: India, Nigeria, Pakistan, Ethiopia, Indonesia, DR Congo.
Some of the global market players in rubella therapy Bayer AG, Novartis AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC, Reckitt Benckiser Group plc, Endo International plc, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi SA, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Merck & Company, Inc., Perrigo Company plc, Abbott Laboratories, Geri-Care Pharmaceuticals Corp., Kopran Ltd. and others.
Request a report for TOC @ https://www.persistencemarketresearch.com/toc/ 23029
Poster of the publication:
7
Source link
